ETV6 and leukemia: By limiting the analysis to leukemia with oncogenic fusions with ≥5 fusion partners (KMT2A24, ETV6, and PAX5), we obtained a statistically significant linear association for KMT2A either when fusions with recurrence >3 were considered (R2 = 0.82; P = 0.002; n = 8; Fig. 2l) or when fusions with recurrence >1 were considered (R2 = 0.86; P = 1.5 × 10−5; n = 12; Supplementary Fig. 3i) but not for ETV6 and PAX5 (P > 0.1; Supplementary Fig. 3j, k).